A case of zolbetuximab-induced protein-losing gastroenteropathy in a patient with advanced gastric cancer.

IF 0.5 Q4 ONCOLOGY

International Cancer Conference Journal Pub Date : 2025-04-11 eCollection Date: 2025-07-01 DOI:10.1007/s13691-025-00764-z

Kunihiro Tsuji, Kito Yosuke, Saori Miyajima, Sho Tsuyama

引用次数: 0

Abstract

Zolbetuximab is a monoclonal antibody targeting Claudin 18.2 that has been approved for the treatment of advanced gastric cancer in Japan. Zolbetuximab has its anticancer effects through a variety of mechanisms, including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Previous studies have identified edema and hypoalbuminemia as adverse events associated with zolbetuximab treatment although the mechanisms underlying these effects remain unclear. In this report, we present a case of zolbetuximab-inducing protein-losing gastroenteropathy in a patient with advanced gastric cancer. This case demonstrated protein leakage from the upper gastrointestinal tract, confirmed through protein leakage scintigraphy. This finding could provide the mechanisms of zolbetuximab-induced edema and hypoalbuminemia.

查看原文本刊更多论文

唑苯妥昔单抗致晚期胃癌患者失蛋白性胃肠病1例。

Zolbetuximab是一种靶向Claudin 18.2的单克隆抗体，已在日本被批准用于治疗晚期胃癌。Zolbetuximab通过多种机制发挥其抗癌作用，包括抗体依赖性细胞毒性和补体依赖性细胞毒性。先前的研究已经确定水肿和低白蛋白血症是与唑苯妥昔单抗治疗相关的不良事件，尽管这些影响的机制尚不清楚。在这个报告中，我们提出了一例唑苯妥昔单抗诱导的蛋白质丢失性肠胃病患者与晚期胃癌。本病例表现为上消化道蛋白质渗漏，通过蛋白质渗漏显像证实。这一发现可能提供唑苯妥昔单抗诱导水肿和低白蛋白血症的机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Cancer Conference Journal ONCOLOGY-

自引率

14.30%

发文量

期刊介绍： This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)